Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch <i>et al</i>.

Chheda, Zinal S; Mueller, Sabine; Hegde, Bindu; Yamamichi, Akane; Butterfield, Lisa H; Okada, Hideho

Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al.

Chheda, Zinal S; Mueller, Sabine; Hegde, Bindu; Yamamichi, Akane; Butterfield, Lisa H; Okada, Hideho.

Afiliação

Chheda ZS; Sanofi Genzyme, Cambridge, Massachusetts, USA.
Mueller S; Department of Neurology, UCSF, San Francisco, California, USA.
Hegde B; Department of Neurosurgery, UCSF, San Francisco, California, USA.
Yamamichi A; Department of Pediatrics, UCSF, San Francisco, California, USA.
Butterfield LH; Children's University Hospital, Zurich, Switzerland.
Okada H; 3T Biosciences Inc, Palo Alto, California, USA.

J Immunother Cancer ; 11(3)2023 03.

Article em En | MEDLINE | ID: mdl-36944450

Assuntos

Glioma; Antígeno HLA-A2; Humanos; Antígeno HLA-A2/genética; Histonas/genética; Imunoterapia; Glioma/genética; Glioma/terapia; Mutação

Palavras-chave

Antigens, Neoplasm; Brain Neoplasms; CD8-Positive T-Lymphocytes; Immunotherapy; T-Lymphocytes

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígeno HLA-A2 / Glioma Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google